Production (Stage)
Kiniksa Pharmaceuticals International, plc
KNSA
$30.23
$0.712.41%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 148.23% | -135.22% | 8.39% | -126.10% | -44.29% |
| Total Depreciation and Amortization | -25.97% | -25.93% | -33.83% | -28.57% | -21.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.37% | 138.43% | -76.83% | 238.95% | 76.96% |
| Change in Net Operating Assets | -81.36% | 618.48% | -49.12% | -66.19% | 3,199.23% |
| Cash from Operations | 459.92% | 333.99% | -113.16% | 238.07% | 193.44% |
| Capital Expenditure | -17.86% | -244.64% | 100.00% | 100.00% | -250.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -300.88% | 541.34% | 48.23% | -231.64% | 167.57% |
| Cash from Investing | -301.93% | 538.38% | 48.29% | -231.70% | 167.31% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -20.38% | 184.22% | 467.35% | 96.71% | 683.14% |
| Repurchase of Common Stock | -8.14% | -120.61% | -145.43% | -213.37% | 9.29% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -23.39% | 208.20% | 1,111.78% | -212.66% | 3,914.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -179.85% | 973.05% | -136.02% | -230.86% | 178.68% |